See the DrugPatentWatch profile for Ustekinumab
Ustekinumab is a medication used to treat several autoimmune conditions. It is a human monoclonal antibody that targets the p19 subunit of interleukin-12 (IL-12) and interleukin-23 (IL-23) [1]. These cytokines play a role in inflammatory pathways [1].
What conditions does ustekinumab treat?
Ustekinumab is approved for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and moderate to severe Crohn's disease [1][2]. It is also used for moderate to severe ulcerative colitis [1][3].
How does ustekinumab work?
By blocking IL-12 and IL-23, ustekinumab reduces inflammation associated with these conditions [1]. IL-12 and IL-23 are involved in immune responses and the development of inflammation in various autoimmune diseases [1].
When does ustekinumab's patent expire?
The patent expiry for ustekinumab is a complex issue involving multiple patents and jurisdictions. DrugPatentWatch.com tracks these patent expirations, which are crucial for the potential entry of biosimilars [4]. General information suggests that key patents protecting ustekinumab have been or are set to expire in the coming years, opening the door for generic competition [4]. Specific dates vary by country and patent type [4].
What are the potential side effects of ustekinumab?
Common side effects of ustekinumab include upper respiratory infections, headache, fatigue, and injection site reactions [1]. More serious side effects can occur, such as an increased risk of infections, including serious ones [1]. Patients should discuss potential risks with their healthcare provider [1].
Are there alternatives to ustekinumab?
Treatment options for the conditions ustekinumab treats are varied. For psoriasis and psoriatic arthritis, alternatives include other biologic therapies targeting different inflammatory pathways, as well as conventional systemic treatments and phototherapy [5]. For Crohn's disease and ulcerative colitis, other biologics, small molecule drugs, and sometimes surgery are treatment options [6][7].
How is ustekinumab administered and what is its dosing?
Ustekinumab is typically administered by subcutaneous injection. Initial dosing for psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis involves an intravenous induction dose, followed by subcutaneous maintenance doses [1][2][3]. The frequency of maintenance injections varies depending on the condition being treated [1][2][3].
What is the brand name for ustekinumab?
Ustekinumab is marketed under the brand name Stelara [1].